Your session is about to expire
← Back to Search
CAR T-Cell Therapy for Glioblastoma
Study Summary
This trial is testing the effects of brain tumor-specific immune cells on patients with leptomeningeal disease from glioblastoma, ependymoma or medulloblastoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am willing to pause my current cancer treatments for the study.You have a condition where your immune system attacks your own body.I can care for myself but may need occasional help.I am not pregnant or will use birth control during and after the study.I need extra oxygen to maintain my oxygen levels above 95%, and this won't improve in 2 weeks.I have seizures that medication can't control or worsening brain function.I do not have any uncontrolled illnesses or active infections, including hepatitis B or C.I have a bleeding disorder or cannot stop my blood thinner safely for a procedure.I am not pregnant or breastfeeding.I have a long-lasting or active virus infection in my brain or spinal cord.My shunt valve is programmable and can be turned off for 48 hours.I have another active cancer besides the one being studied.My cancer has spread to the lining of my brain and spinal cord.I have no allergies or adverse reactions to leukapheresis, steroids, or tocilizumab.I require dialysis.I understand the study's purpose, procedures, and the risks/benefits of participating.My tumor tests positive for IL13Ralpha2.
- Group 1: Treatment (IL13Ralpha2-CAR T cells)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there opportunities currently open to join this research endeavor?
"According to information found on the clinicaltrials.gov website, enrollment for this trial is still open. The study was initially posted in March 5th 2021 and has been amended as ofMarch 9th 2022."
What is the upper limit of people participating in this investigation?
"Affirmative. According to the clinicaltrials.gov website, this research initiative is actively seeking participants and was initially published on March 5th 2021; it has since been updated on March 9th 2022. The study requires 30 volunteers to be sourced from a single site."
Has the FDA approved IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes for therapeutic use?
"Due to the limited clinical data available, our team has assigned a score of 1 for the safety of IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes in this Phase 1 trial."
Share this study with friends
Copy Link
Messenger